Enbrel gets highest rating among RA biologicals by surveyed US patients
For surveyed rheumatoid arthritis (RA) patients on biologic therapy, the benefits outweigh the risks for all of the available biologic agents. According to PatientTrends: Rheumatoid Arthritis (US) 2012 from Decision Resources unit BioTrends Research, Amgen and Pfizer’s Enbrel (etanercept) received the highest ratings in several categories.
The ability to reduce and/or eliminate the symptoms of RA was highly rated for Enbrel, and more than one-half of surveyed RA patients taking Enbrel also reported no side effects. With the exception of reverse joint damage, biologic therapy seems to be addressing the symptoms of RA, according to surveyed patients. However, patients also view biologics as increasing their chances of catching serious infections and developing certain types of cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze